On Apr. 14, 2020, NantKwest and ImmunityBio announced discussions with the FDA for vaccines and therapeutics to combat COVID-19. The companies have developed immunomodulator regimens for COVID-19 based on the biological stage of the patientﾒs infection – from the mild, moderate to the severe or critically ill state.

NantKwest and Immunity Bio proposed clinical trials of N-803 alone, and a second trial of haNK alone, or haNK combined with convalescent plasma. NantKwest has filed an IND with the FDA and anticipated the start of trials in Q2 2020.